Minimizing systemic absorption of topically administered ophthalmic drugs.
about
Carbopol/chitosan based pH triggered in situ gelling system for ocular delivery of timolol maleateLondon 2012: prescribing for athletes in ophthalmologySystemic side effects of eye drops: a pharmacokinetic perspectivesFlt Multivalent Conjugates Inhibit Angiogenesis and Improve Half-Life In VivoSolid lipid nanoparticles for ocular drug delivery.Prednisolone-loaded nanocapsules as ocular drug delivery system: development, in vitro drug release and eye toxicity.Tear-mediated delivery of nanoparticles through transcytosis of the lacrimal glandNovel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.Cyclodextrins in drug delivery.Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and SwedenDrug metabolism and pharmacokinetics.Polymeric vectors for ocular gene delivery.Nanoparticles laden in situ gelling system for ocular drug targeting.Rho-kinase inhibitors offer a new approach in the treatment of glaucoma.A review of topically administered mini-tablets for drug delivery to the anterior segment of the eye.Liposomes in topical ophthalmic drug delivery: an update.Pharmacokinetics of intravitreal antibiotics in endophthalmitis.In vitro testing of thiolated poly(aspartic acid) from ophthalmic formulation aspects.Minimally invasive microneedles for ocular drug delivery.A comprehensive insight on ocular pharmacokinetics.Passive and oxymetazoline-enhanced delivery with a lens device: pharmacokinetics and efficacy studies with rabbits.Topical brinzolamide and metabolic acidosisDesign and characterization of chitosan-alginate microspheres for ocular delivery of azelastine.The birth of ocular pharmacology in the 20th century.Ocular and systemic pharmacokinetics of lidocaine hydrochloride ophthalmic gel in rabbits after topical ocular administration.Topical phenylephrine induced pulmonary odema: few suggestions.The effect of needle gauge, needle type, and needle orientation on the volume of a drop.Role of intravitreal/intracameral antibiotics to prevent traumatic endophthalmitis - Meta-analysis.Evaluation of the in vivo behaviour of gentamicin sulphate ocular mini-tablets in ponies.High-precision piezo-ejection ocular microdosing: Phase II study on local and systemic effects of topical phenylephrine.Tear dynamics model.A mathematical model for ocular tear and solute balance.Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases.The design of contact lens based ocular drug delivery systems for single-day use: Part (I) Structural factors, surrogate ophthalmic dyes and passive diffusion studies.Evaluation of subconjunctival liposomal steroids for the treatment of experimental uveitis.
P2860
Q24623638-24B4AC11-ABB0-406C-AAB7-5BC676BBE4F7Q26996815-DB6997BA-8431-453B-871D-46553C2096EBQ28066720-493DEE90-C8DC-4EE0-B0D1-5A75257B5223Q28552652-9FF22808-D6AA-4192-A7AB-2436CE37502EQ34116807-41217D6F-F648-4B4B-85B8-5C0398DE1D0DQ35138918-8845CAA4-C4BC-44AF-8F25-5A4CA73683CBQ35684758-14825038-CE38-46FB-98F7-8D127C4B1B1DQ35696092-FAE7102B-2025-4596-99B3-1901597A061CQ36316735-7514EA39-507A-4BEC-9A5B-EE051A5B2EACQ37318853-8F6BC05D-7A04-4E3C-8D60-FA04C9C4DF42Q37550548-485ACC89-66B2-4349-8A4B-0C4662B9EC3CQ37920729-193E91F9-C828-4144-962A-AEC8A89F12B9Q38105564-9EE9734B-EE99-4607-AD60-3804ABEEEBF5Q38149325-4726AE01-EE5E-4DFF-AB95-C7A38C8ADC02Q38196445-6CA582BF-B83F-4C8B-8E71-C04BC4D0BC88Q38239330-79E696C2-2CE0-4EB3-A52A-13566779057AQ38350572-6A2080B4-3AE7-479A-B6F7-8EADA5715241Q38820385-1654B9F0-EF25-4FAC-8F8E-0E252EB02CC6Q38916649-B2A994D0-DA7B-4046-8004-A92D423E6D6CQ38995367-26D7CD4B-CC02-4893-B589-21C37B742801Q42036571-4965FEAB-16AC-48F0-A813-D9AFEBB7A7FEQ42835952-BE0172BD-FA51-4DEA-A892-F709A652F901Q44187608-90F51821-1BB4-49FD-962E-C6295873AB12Q44875663-BBFBF8AB-DD34-4665-A695-B386E2D9DDB5Q45929402-012121F2-A161-49A1-91E1-25DF97D57B08Q46005669-A7DCE0C9-6136-44B6-98E1-6D81828DA9EFQ46896361-95D9FA18-99D3-423D-95CD-F9AC9A641521Q47392183-CB042F0C-1929-49F1-BB78-60DFAED00D15Q49044644-2DF2E3D1-8A40-40E1-906F-52DF97CD52BBQ50094851-FBD36BCB-8422-4317-9E2C-574C1C911759Q51019507-B060E898-EC79-4E31-877C-CFBCF1D70F8EQ51330174-E5F5AFA5-6481-438A-AD1B-F75409133C7AQ52679059-93DDCC64-F5B5-4F33-A618-4AC6540749D8Q53591049-2B8AC6C3-3B55-4FEA-B6E7-5DBA07A3FEA6Q55176472-6F3FB986-8190-47C4-9CD3-EB016C8C7CDF
P2860
Minimizing systemic absorption of topically administered ophthalmic drugs.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Minimizing systemic absorption of topically administered ophthalmic drugs.
@en
type
label
Minimizing systemic absorption of topically administered ophthalmic drugs.
@en
prefLabel
Minimizing systemic absorption of topically administered ophthalmic drugs.
@en
P1476
Minimizing systemic absorption of topically administered ophthalmic drugs.
@en
P2093
P304
P356
10.1016/0039-6257(93)90141-S
P577
1993-05-01T00:00:00Z